{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T10:14:19Z","timestamp":1771496059307,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016016","name":"Gilead UK and Ireland Corporate Contributions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jtocrr.2025.100929","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:23:17Z","timestamp":1761855797000},"page":"100929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7369-4512","authenticated-orcid":false,"given":"Niels","family":"Reinmuth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Couraud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Chiara","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shobhit","family":"Baijal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davey","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terufumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivor","family":"Percent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achim","family":"Rittmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector Soto","family":"Parra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabeen","family":"Mekan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Radford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher G.","family":"Pelligra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shien","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2025.100929_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtocrr.2025.100929_bib2","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2025.100929_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4143\/crt.2022.264","article-title":"Five-year overall survival and prognostic factors in patients with lung cancer: results from the Korean Association of Lung Cancer Registry (KALC-R) 2015","volume":"55","author":"Jeon","year":"2023","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.jtocrr.2025.100929_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jtho.2022.09.005","article-title":"Stage shift improves lung cancer survival: real-world evidence","volume":"18","author":"Yang","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2025.100929_bib6","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.3390\/cancers15235505","article-title":"Future perspectives in the second line therapeutic setting for non-oncogene addicted non-small-cell lung cancer","volume":"15","author":"Siringo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2025.100929_bib7","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1200\/JCO.23.00282","article-title":"Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO living guideline, version 2023.1","volume":"41","author":"Singh","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2025.100929_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107451","volume":"189","author":"Paz-Ares","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100929_bib9","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1200\/JCO.23.02166","article-title":"CONTACT-01: a randomized phase III trial of atezolizumab + cabozantinib versus docetaxel for metastatic non-small cell lung cancer after a checkpoint inhibitor and chemotherapy","volume":"42","author":"Neal","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2025.100929_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1247879","article-title":"Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review","volume":"13","author":"Garon","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtocrr.2025.100929_bib12","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label Phase III EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2025.100929_bib13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.jtocrr.2025.100929_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40268-024-00478-2","article-title":"The importance of patient reported outcomes in oncology clinical trials and clinical practice to inform regulatory and healthcare decision-making","volume":"24","author":"Bellino","year":"2024","journal-title":"Drugs R D"},{"key":"10.1016\/j.jtocrr.2025.100929_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2021.100642","article-title":"Non-small cell lung cancer symptom assessment questionnaire: psychometric performance and regulatory qualification of a novel patient-reported symptom measure","volume":"95","author":"Bushnell","year":"2021","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.jtocrr.2025.100929_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtocrr.2025.100929_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"10.1016\/j.jtocrr.2025.100929_bib19","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"10.1016\/j.jtocrr.2025.100929_bib20","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jval.2017.09.009","article-title":"Informing the tolerability of cancer treatments using patient-reported outcome measures: summary of an FDA and critical path institute workshop","volume":"21","author":"Kluetz","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.jtocrr.2025.100929_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"35","author":"Kluetz","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtocrr.2025.100929_bib22","series-title":"Psychometric Validation and Meaningful Within-Patient Change (MWPC) Thresholds for the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) Using Data From the EVOKE-01 Study (Poster PCR54). Poster Presented at: ISPOR Europe 2024","author":"Patel","year":"2024"},{"key":"10.1016\/j.jtocrr.2025.100929_bib23","author":"HTA"},{"key":"10.1016\/j.jtocrr.2025.100929_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2023.04.027","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types","volume":"188","author":"Musoro","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2025.100929_bib25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2025.100929_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2025.100929_bib27","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2025.100929_bib28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jtocrr.2025.100929_bib29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2025.100929_bib30","series-title":"Self-Reported Population Health: an International Perspective Based on EQ-5D","first-page":"19","article-title":"Population norms for the EQ-5D","author":"Janssen","year":"2014"},{"key":"10.1016\/j.jtocrr.2025.100929_bib31","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.lungcan.2013.03.008","article-title":"Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany","volume":"81","author":"Iyer","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100929_bib32","first-page":"1023","article-title":"Quality of life of patients with lung cancer","volume":"9","author":"Polanski","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jtocrr.2025.100929_bib33","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/bjc.2013.585","article-title":"Quality of life during chemotherapy in lung cancer patients: results across different treatment lines","volume":"109","author":"Wintner","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtocrr.2025.100929_bib34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cllc.2020.06.014","article-title":"What goals do patients and oncologists have when starting medical treatment for metastatic lung cancer?","volume":"22","author":"Mieras","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100929_bib35","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.3390\/cancers13174282","article-title":"Health-related quality of life and survival in metastasized non-small cell lung cancer patients with and without a targetable driver mutation","volume":"13","author":"Billingy","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2025.100929_bib36","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jtho.2019.01.016","article-title":"Health-related quality of life in KEYNOTE-010: a Phase II\/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC","volume":"14","author":"Barlesi","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2025.100929_bib37","doi-asserted-by":"crossref","first-page":"17403","DOI":"10.1002\/cam4.6361","article-title":"The effects of tislelizumab treatment on the health-related quality of life of patients with advanced non-small cell lung cancer","volume":"12","author":"Huang","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtocrr.2025.100929_bib38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jtho.2017.10.029","article-title":"Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non-small cell lung cancer: results from the CheckMate 017 study","volume":"13","author":"Reck","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2025.100929_bib39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2018.05.005","article-title":"Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057","volume":"102","author":"Reck","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2025.100929_bib40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejca.2014.11.015","article-title":"Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer","volume":"51","author":"Novello","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2025.100929_bib41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2016.01.007","article-title":"Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced\/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy","volume":"93","author":"P\u00e9rol","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100929_bib42","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cllc.2018.05.011","article-title":"Patient-reported outcomes in OAK: A Phase III study of atezolizumab versus docetaxel in advanced non-small-cell lung cancer","volume":"19","author":"Bordoni","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100929_bib43","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266636432500147X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266636432500147X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:58:14Z","timestamp":1771491494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266636432500147X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S266636432500147X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100929","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100929"}}